Iron therapy: Indications, limitations and modality;Supplémentation en fer : Indications, limites et modalités

Revue de Medecine Interne

Volumn 34, Issue 1, 2013, Pages 26-31

  Arlet, J B ^a,b   Pouchot, J ^a   Lasocki, S ^c   Beaumont, C ^a,d   Hermine, O ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CNRS   (France)

^c UNIVERSITÉ D'ANGERS   (France)

^d CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

Anemia of chronic disease; Erythropoiesis; Hepcidin; Iron; Iron deficiency

Indexed keywords

IRON;

ANEMIA; DRUG INDICATION; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; PATHOPHYSIOLOGY; SHORT SURVEY; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANEMIA; ANEMIA, IRON-DEFICIENCY; ANTIMICROBIAL CATIONIC PEPTIDES; CHRONIC DISEASE; CLINICAL PROTOCOLS; HUMANS; IRON;

EID: 84871676597     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2012.04.007     Document Type: Short Survey

References (38)

1. Cazzola M., Bergamaschi G., Dezza L., Arosio P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 1990, 75:1903.
2. Beaumont C., Karim Z. L'actualité du métabolisme du fer. Rev Med Interne 2012, [in press]. 10.1016/j.revmed.2012.04.006.
3. Cadet E., Gadenne M., Capron D., Rochette J. Données récentes sur le métabolisme du fer : un état de transition. Rev Med Interne 2005, 26:315-324.
4. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
5. Arlet J.B., Hermine O., Darnige L., Ostland V., Westerman M., Badoual C., et al. Iron-deficiency anemia in Castleman disease: implication of the interleukin 6/hepcidin pathway. Pediatrics 2010, 126:e1608-e1612.
6. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113:1271-1276.
7. Muñoz M., García-Erce J.A., Remacha á.F. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol 2011, 64:287-296.
8. Fishbane S. Review of issues relating to iron and infection. Am J Kidney Dis 1999, 34. 34S47-52.
9. Sunder-Plassmann G., Patruta S.I., Hörl W.H. Pathobiology of the role of iron in infection. Am J Kidney Dis 1999, 34:S25-S29.
10. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
11. Lasocki S., Longrois D., Montravers P., Beaumont C. Hepcidin and anemia of the critically ill patient. Anesthesiology 2011, 114:688-694.
12. Lambert J.F., Beris P. Pathophysiology and differential diagnosis of anaemia. The Handbook 2009, 4:109-139. ESH, Paris. C. Beaumont, P. Beris, Y. Beuzard, C. Brugnara (Eds.).
13. Brugnara C., Beris P. Iron therapy. The Handbook 2009, 21:513-526. ESH, Paris. C. Beaumont, P. Beris, Y. Beuzard, C. Brugnara (Eds.).
14. Beutler E., Larsh S.E., Gurney C.W. Iron therapy in chronically fatigued, nonanemic women: a double-blind study. Ann Intern Med 1960, 52:378-394.
15. Verdon F., Burnand B., Stubi C.L., Bonard C., Graff M., Michaud A., et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 2003, 326:1124.
16. Bruner A.B., Joffe A., Duggan A., Casella J.F., Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient girls. Lancet 1996, 348:992-996.
17. Murray-Kolb L.E., Beard J.L. Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr 2007, 85:778-787.
18. Agarwal R. Nonhematological benefits of iron. Am J Nephrol 2007, 27:565-571.
19. Favier M., Hininger-Favier I. Faut-il supplémenter en fer les femmes enceintes ?. Gynecol Obstet Fertil 2004, 32:245-250.
20. Peña-Rosas J.P., Viteri F.E. Effects and safety of preventive oral iron oriron+folic acid supplementation for women during pregnancy. Cochrane Database Syst Rev 2009, 4:CD004736.
21. Johnson-Wimbley T.D., Graham D.Y. Diagnosis and management of iron deficiency anemia in the 21st century. Ther Adv Gastroenterol 2011, 4:177-184.
22. Lyseng-Williamson K.A., Keating G.M. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009, 69:739-756.
23. Ganzoni A.M. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970, 100:301-303.
24. Evstatiev R., Marteau P., Iqbal T., Khalif I.L., Stein J., Bokemeyer B., et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011, 141:846-853.
25. Maynor L., Brophy D.F. Risk of infection with intravenous iron therapy. Ann Pharmacother 2007, 41:1476-1480.
26. Anker S.D., Comin Colet J., Filippatos G., Willenheimer R., Dickstein K., Drexler H., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009, 361:2436-2448.
27. Jankowska E.A., Rozentryt P., Witkowska A., Nowak J., Hartmann O., Ponikowska B., et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010, 31:1872-1880.
28. Sasu B.J., Cooke K.S., Arvedson T.L., Plewa C., Ellison A.R., Sheng J., et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010, 115:3616-3624.
29. Sloand J.A., Shelly M.A., Feigin A., Bernstein P., Monk R.D. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004, 43:663-670.
30. Grote L., Leissner L., Hedner J., Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in thetreatment of restless legs syndrome. Mov Disord 2009, 24:1445-1452.
31. Wang J., O'Reilly B., Venkataraman R., Mysliwiec V., Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study. Sleep Med 2009, 10:973-975.
32. Krayenbuehl P.A., Battegay E., Breymann C., Furrer J., Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011, 118:3222-3227.
33. Callens C., Coulon S., Naudin J., Radford-Weiss I., Boissel N., Raffoux E., et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 2010, 207:731-750.
34. Lovejoy D.B., Richardson D.R. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem 2003, 10:1035-1049.
35. Buss J.L., Torti F.M., Torti S.V. The role of iron chelation in cancer therapy. Curr Med Chem 2003, 10:1021-1034.
36. Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J., et al. Recombinant human erythropoiesis-stimulatingagents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373:1532-1542.
37. Rizzo J.D., Brouwers M., Hurley P., Seidenfeld J., Arcasoy M.O., Spivak J.L., et al. Practice Guideline Update Committee. American Society of Hematology/AmericanSociety of Clinical Oncology clinical practice guideline update on the use ofepoetin and darbepoetin in adult patients with cancer. Blood 2010, 116:4045-4059.
38. Auerbach M., Ballard H., Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007, 369:1502-1504.